Vergent Bioscience Reports Promising Phase 2B Results for Abenacianine, Advancing Real-Time Tumor Imaging During Lung Cancer Surgery Vergent Bioscience, a clinical-stage biotechnology company focused on developing innovative tumor-targeted imaging technologies,…
Mainstay Medical Achieves Coverage Milestone with Highmark Mainstay Medical Holdings plc has announced a significant reimbursement milestone for its ReActiv8 Restorative Neurostimulation™ therapy, following a favorable coverage decision from Highmark…
Shionogi Launches XOCOVA® in the United States as the First Oral Post-Exposure COVID-19 Prevention Therapy Shionogi Inc., the U.S. subsidiary of Japan-based pharmaceutical company Shionogi & Co., Ltd., has announced…
Secretome Therapeutics Strengthens Executive Leadership Team to Advance Rare Disease Pipeline and Regenerative Medicine Platform Secretome Therapeutics, a clinical-stage biotechnology company developing regenerative therapies derived from neonatal cardiac progenitor cells…
Feinstein Institutes Reveals the World’s First Comprehensive Vagus Nerve Map Northwell Health’s Feinstein Institutes for Medical Research has announced the release of the world’s first comprehensive anatomical map of the…
Sarepta Therapeutics Appoints Michael Severino as Chief Executive Officer to Lead Next Phase of Precision Genetic Medicine Growth Sarepta Therapeutics, Inc., a global biotechnology company recognized for its leadership in…
bioAffinity Technologies Publishes Clinical White Paper Highlighting Practical Use of CyPath® Lung for Pulmonary Nodule Risk Assessment bioAffinity Technologies, Inc., a biotechnology company dedicated to advancing noninvasive diagnostics and early…
Spruce Biosciences Strengthens Executive Leadership with Appointment of Rare Disease Expert as Chief Medical Officer Spruce Biosciences, Inc., a late-stage biopharmaceutical company dedicated to developing innovative therapies for neurological disorders…
Enhanced Group Applauds FDA Advisory Committee Recommendation Supporting Regulated Access to Therapeutic Peptides Enhanced Group Inc. (NYSE: ENHA), a company focused on elite sports performance, personalized health optimization, and evidence-based…
Precision BioSciences Strengthens Executive Leadership to Support Clinical Growth and Advance Gene Editing Pipeline Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage gene editing company focused on developing transformative in vivo…
Gossamer Bio Advances Toward NDA Submission for Seralutinib, Reacquires Global Rights, and Strengthens Strategic Position Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for…
Yarrow Bioscience Completes Merger with VYNE Therapeutics and Secures Approximately $200 Million to Advance First-in-Class Autoimmune Thyroid Disease Program Yarrow Bioscience, Inc., a clinical-stage biotechnology company dedicated to developing innovative…